We're proud to announce that Aaron Edwards, Co-Founder of KiraGen Bio, has recently published a compelling blog post for Harvard Business School, detailing his summer internship experience at Eli Lilly. The post offers an in-depth look into the critical role of integrating science with business strategies, a core value that underpins KiraGen Bio's approach. Aaron shares his journey, exploring the challenges of bringing scientific innovations to market and the strategic insights gained. This publication underscores the importance of fostering a deep connection between biotechnological research and commercial acumen. Join us in celebrating Aaron's contribution and gain insights from his experiences by reading the full blog post. Click here to read Aaron's story: https://www.hbs.edu/mba/blog/post/bridging-science-and-business-my-summer-internship-at-eli-lilly.

KiraGen is honored to announce our latest achievement – taking home the top prize at the Harvard Undergraduate Capital Partners Innovation Fund x Consulting, Business, and the Environment Ventures Competition. This accolade is a significant affirmation of our dedication to revolutionizing cancer treatment through our innovative CAR-T cell therapies. Receiving this recognition is a milestone that not only validates our scientific and entrepreneurial efforts but also propels us forward with additional resources and support. The award, a testament to our team's hard work and the potential of our technology, provides us with invaluable opportunities, including a prioritized application to become part of the Z Fellows Program. This would enable us to immerse ourselves in intensive development, guided by mentorship from leading experts, and to collaborate with a cohort of exceptional technical builders. We're deeply thankful for this honor and remain committed to our mission to deliver transformative solutions in the fight against cancer.

Ryan Murray, the visionary Co-Founder and Chief Scientific Officer of KiraGen Bio, has been selected to join the esteemed third cohort of the Fifty 50 program, hosted by the tech bio VC firm Fifty Years. This exclusive initiative is dedicated to empowering bio and climate-focused innovators, including seasoned founders, PhDs, and postdocs, aiming to translate their groundbreaking lab work into scalable solutions with a significant positive impact. Murray's inclusion in Fifty 50 underscores his commitment to pioneering advancements in CAR-T cell therapies and combinatorial gene editing, aligning with KiraGen Bio's mission to redefine cancer treatment. Through this program, Murray will further hone his expertise in commercializing science, potentially setting new standards in the biotech industry